(Q43672293)

25 November 2017

title

Factors influencing ribavirin-induced hemolysis (English)

1 reference

25 November 2017

1 reference

H Van Vlierbergh

1

1 reference

25 November 2017

J R Delanghe

2

1 reference

25 November 2017

M De Vos

3

1 reference

25 November 2017

G Leroux-Roel

4

1 reference

25 November 2017

BASL Steering Committee

5

1 reference

25 November 2017

publication date

1 June 2001

1 reference

25 November 2017

published in

Journal of Hepatology

1 reference

25 November 2017

volume

34

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

911-916

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Hemolytic anemia and the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Therapy of hepatitis C: alpha interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Zone electrophoresis in starch gels: group variations in the serum proteins of normal human adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

MedCalc: a new computer program for medical statistics.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Haptoglobin polymorphism and peripheral arterial occlusive disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

Biological and clinical significance of haptoglobin polymorphism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900029-0

7 January 2021

10.1016/S0168-8278(01)00029-0

Identifiers

DOI

1 reference

25 November 2017

1 reference